General Information of Drug (ID: DMEVGI9)

Drug Name
SPK-7001 Drug Info
Indication
Disease Entry ICD 11 Status REF
Choroidal dystrophy 9B61 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMEVGI9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BIIB111 DMQCE1T Choroideremia 9B61 Phase 3 [2]
4D-110 DMUXAM8 Choroideremia 9B61 Phase 1 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Rab proteins geranylgeranyltransferase component A 1 (CHM) TTOA18V RAE1_HUMAN Replacement [1]

References

1 Clinical pipeline report, company report or official report of Spark Therapeutics.
2 ClinicalTrials.gov (NCT03496012) A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1). U.S.National Institutes of Health.
3 Clinical pipeline report, company report or official report of 4D Molecular Therapeutics